Levofloxacin in the treatment of community-acquired pneumonia

Expert Review of Anti-Infective Therapy

Volumn 8, Issue 5, 2010, Pages 505-514

  Noreddin, Ayman M ^a   Elkhatib, Walid F ^b,c  

^a HAMPTON UNIVERSITY   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c African Union Organization St Abbassia   (Egypt)

Author keywords

Community acquired pneumonia; Fluoroquinolones; Levofloxacin; Pharmacodynamics; Pharmacokinetics; Therapeutic use; Tolerability

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CILASTATIN PLUS IMIPENEM; CLINDAMYCIN; LEVOFLOXACIN; PENICILLIN G; PLACEBO;

ABDOMINAL PAIN; ACUTE PYELONEPHRITIS; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; BACTERIAL SINUSITIS; BACTERICIDAL ACTIVITY; BIOEQUIVALENCE; COMMUNITY ACQUIRED PNEUMONIA; CONSTIPATION; DIARRHEA; DISTRIBUTION VOLUME; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG TOLERABILITY; DYSPEPSIA; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; INSOMNIA; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NAUSEA; NONHUMAN; PATIENT COMPLIANCE; PHARMACODYNAMICS; POSTMARKETING SURVEILLANCE; REVIEW; SINGLE DRUG DOSE; URINARY TRACT INFECTION; VOMITING;

AGED; ANTI-BACTERIAL AGENTS; CLINICAL TRIALS AS TOPIC; COMMUNITY-ACQUIRED INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; OFLOXACIN; PNEUMONIA, BACTERIAL; TREATMENT OUTCOME;

EID: 77952271412     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.10.35     Document Type: Review

References (93)

1. Almirall J, Bolibar I, Vidal J et al.. Epidemiology of community-acquired pneumonia in adults: a population-based study. Eur. Respir. J. 15(4), 757-763 (2000).
2. Gutierrez F, Masia M, Rodriguez JC et al.. Epidemiology of community-acquired pneumonia in adult patients at the dawn of the 21st century: a prospective study on the Mediterranean coast of Spain. Clin. Microbiol. Infect. 11(10), 788-800 (2005).
3. Loh LC, Khoo SK, Quah SY et al.. Adult community-acquired pneumonia in Malaysia: prediction of mortality from severity assessment on admission. Respirology 9(3), 379-386 (2004).
4. O'Meara ES, White M, Siscovick DS, Lyles MF, Kuller LH. Hospitalization for pneumonia in the cardiovascular Health Study: incidence, mortality, and inf luence on longer-term survival. J. Am. Geriatr. Soc. 53(7), 1108-1116 (2005).
5. Gutierrez F, Masia M, Mirete C et al.. The influence of age and gender on the population-based incidence of community-acquired pneumonia caused by different microbial pathogens. J. Infect. 53(3), 166-174 (2006).
6. Kaplan V, Angus DC. Community-acquired pneumonia in the elderly. Crit. Care Clin. 19(4), 729-748 (2003).
7. Viegi G, Pistelli R, Cazzola M et al.. Epidemiological survey on incidence and treatment of community acquired pneumonia in Italy. Respir. Med. 100(1), 46-55 (2006).
8. Colice GL, Morley MA, Asche C, Birnbaum HG. Treatment costs of community-acquired pneumonia in an employed population. Chest 125(6), 2140-2145 (2004).
9. Niederman MS, Mandell LA, Anzueto A et al.. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am. J. Respir. Crit. Care Med. 163(7), 1730-1754 (2001).
10. Kollef MH, Shorr A, Tabak YP, Gupta V, Liu LZ, Johannes RS. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest 128(6), 3854-3862 (2005).
11. Bodi M, Rodriguez A, Sole-Violan J et al.. Antibiotic prescription for community-acquired pneumonia in the intensive care unit: impact of adherence to Infectious Diseases Society of America guidelines on survival. Clin. Infect. Dis. 41(12), 1709-1716 (2005).
12. Tejerina E, Frutos-Vivar F, Restrepo MI et al.. Prognosis factors and outcome of community-acquired pneumonia needing mechanical ventilation. J. Crit. Care 20(3), 230-238 (2005).
13. Wilson PA, Ferguson J. Severe community-acquired pneumonia: an Australian perspective. Intern. Med. J. 35(12), 699-705 (2005).
14. Woodhead M, Welch CA, Harrison DA, Bellingan G, Ayres JG. Community-acquired pneumonia on the intensive care unit: secondary analysis of 17,869 cases in the ICNARC case Mix Programme Database. Crit. Care. 10(Suppl. 2), S1 (2006).
15. File TM Jr. Clinical implications and treatment of multiresistant Streptococcus pneumoniae pneumonia. Clin. Microbiol. Infect. 12(Suppl. 3), 31-41 (2006).
16. Lauderdale TL, Chang FY, Ben RJ et al.. Etiology of community acquired pneumonia among adult patients requiring hospitalization in Taiwan. Respir. Med. 99(9), 1079-1086 (2005).
17. Leesik H, Ani U, Juhani A, Altraja A. Microbial pathogens of adult community-acquired pneumonia in Southern Estonia. Medicina (Kaunas) 42(5), 384-394 (2006).
18. Luna CM, Famiglietti A, Absi R et al.. Community-acquired pneumonia: etiology, epidemiology, and outcome at a teaching hospital in Argentina. Chest 118(5), 1344-1354 (2000).
19. Huang HH, Zhang YY, Xiu QY et al.. Community-acquired pneumonia in Shanghai, China: microbial etiology and implications for empirical therapy in a prospective study of 389 patients. Eur. J. Clin. Microbiol. Infect. Dis. 25(6), 369-374 (2006).
20. Saito A, Kohno S, Matsushima T et al.. Prospective multicenter study of the causative organisms of community-acquired pneumonia in adults in Japan. J. Infect. Chemother. 12(2), 63-69 (2006).
21. Thibodeau KP, Viera AJ. Atypical pathogens and challenges in community-acquired pneumonia. Am. Fam. Physician 69(7), 1699-1706 (2004).
22. Woodhead M. Community-acquired pneumonia in Europe: causative pathogens and resistance patterns. Eur. Respir. J. Suppl. 36, S20-S27 (2002).
23. File TM Jr, Garau J, Blasi F et al.. Guidelines for empiric antimicrobial prescribing in community-acquired pneumonia. Chest 125(5), 1888-1901 (2004).
24. Mandell LA, Wunderink RG, Anzueto A et al.. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin. Infect. Dis. 44(Suppl. 2), S27-S72 (2007).
25. Woodhead M, Blasi F, Ewig S et al.. Guidelines for the management of adult lower respiratory tract infections. Eur. Respir. J. 26(6), 1138-1180 (2005).
26. Doern GV, Richter SS, Miller A et al.. Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes? Clin. Infect. Dis. 41(2), 139-148 (2005).
27. Bonofiglio L, Ojeda MI, de Mier C et al.. Phenotypic and genotypic characterization of macrolide resistant Streptococcus pneumoniae recovered from adult patients with community-acquired pneumonia in an Argentinian teaching hospital. Int. J. Antimicrob. Agents 25(3), 260-263 (2005).
28. Felmingham D. Comparative antimicrobial susceptibility of respiratory tract pathogens. Chemotherapy. 50(Suppl. 1), 3-10 (2004).
29. Fuller JD, McGeer A, Low DE. Drug-resistant pneumococcal pneumonia: clinical relevance and approach to management. Eur. J. Clin. Microbiol. Infect. Dis. 24(12), 780-788 (2005).
30. Reinert RR, Reinert S, van der Linden M, Cil MY, Al-Lahham A, Appelbaum P. Antimicrobial susceptibility of Streptococcus pneumoniae in eight European countries from 2001 to 2003. Antimicrob. Agents Chemother. 49(7), 2903-2913 (2005).
31. Jones RN, Fritsche TR, Sader HS, Stilwell MG. Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values. Diagn. Microbiol. Infect. Dis. 58(1), 9-17 (2007).
32. Brown SD, Rybak MJ. Antimicrobial susceptibility of Streptococcus pneumoniae, Streptococcus pyogenes and Haemophilus influenzae collected from patients across the USA, in 2001-2002, as part of the PROTEKT US study. J. Antimicrob. Chemother. 54(Suppl. 1), i7-i15 (2004).
33. Doern GV, Brown SD. Antimicrobial susceptibility among community-acquired respiratory tract pathogens in the USA: data from PROTEKT US 2000-2001. J. Infect. 48(1), 56-65 (2004).
34. Hoban D, Waites K, Felmingham D. Antimicrobial susceptibility of community-acquired respiratory tract pathogens in North America in 1999-2000: findings of the PROTEKT surveillance study. Diagn. Microbiol. Infect. Dis. 45(4), 251-259 (2003).
35. Karlowsky JA, Thornsberry C, Jones ME et al.. Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: results from the TRUST Surveillance Program (1998-2002). Clin. Infect. Dis. 36(8), 963-970 (2003).
36. Wang JC. DNA topoisomerases. Annu. Rev. Biochem. 65, 635-692 (1996).
37. Wang JC. A journey in the world of DNA rings and beyond. Annu. Rev. Biochem. 78, 31-54 (2009).
38. Huband MD, Cohen MA, Zurack M et al.. In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/ topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant Gram-positive and fastidious organism groups. Antimicrob. Agents Chemother. 51(4), 1191-1201 (2007).
39. Croom KF, Goa KL. Levofloxacin: a review of its use in the treatment of bacterial infections in the United States. Drugs 63(24), 2769-2802 (2003).
40. Keating GM, Scott LJ. Moxifloxacin: a review of its use in the management of bacterial infections. Drugs 64(20), 2347-2377 (2004).
41. Levaquin® (Levofloxacin tablets, oral solution, injection): US prescribing information. Ortho-McNeil Pharmaceutical, Inc., Raritan, NJ, USA (2009).
42. Hurst M, Lamb HM, Scott LJ, Figgitt DP. Levofloxacin: an updated review of its use in the treatment of bacterial infections. Drugs 62(14), 2127-2167 (2002). (Pubitemid 35204043)
43. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard - seventh edition. Clinical and Laboratory Standards Institute Document M7-A7. Clinical and Laboratory Standards Institute, Wayne, PA, USA (2006).
44. Gordon KA, Sader HS, Jones RN. Contemporary re-evaluation of the activity and spectrum of grepafloxacin tested against isolates in the United States. Diagn. Microbiol. Infect. Dis. 47(1), 377-383 (2003).
45. Fritsche TR, Sader HS, Jones RN. Potency and spectrum of garenoxacin tested against an international collection of skin and soft tissue infection pathogens: report from the SENTRY antimicrobial surveillance program (1999-2004). Diagn. Microbiol. Infect. Dis. 58(1), 19-26 (2007).
46. Goff DA, Dowzicky MJ. Prevalence and regional variation in meticillin-resistant Staphylococcus aureus (MRSA) in the USA and comparative in vitro activity of tigecycline, a glycylcycline antimicrobial. J. Med. Microbiol. 56(Pt 9), 1189-1193 (2007).
47. Biedenbach DJ, Toleman MA, Walsh TR, Jones RN. Characterization of fluoroquinolone-resistant b-hemolytic Streptococcus spp. isolated in North America and Europe including the first report of fluoroquinolone-resistant Streptococcus dysgalactiae subspecies equisimilis: report from the SENTRY Antimicrobial Surveillance Program (1997-2004). Diagn. Microbiol. Infect. Dis. 55(2), 119-127 (2006).
48. Nilius AM, Shen LL, Hensey-Rudloff D et al.. In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone. Antimicrob. Agents Chemother. 47(10), 3260-3269 (2003).
49. Jacobs MR, Felmingham D, Appelbaum PC, Gruneberg RN, Alexander Project Group. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J. Antimicrob. Chemother. 52(2), 229-246 (2003).
50. Soriano F, Granizo JJ, Coronel P et al.. Antimicrobial susceptibility of Haemophilus influenzae, Haemophilus parainfluenzae and Moraxella catarrhalis isolated from adult patients with respiratory tract infections in four southern European countries. The ARISE project. Int. J. Antimicrob. Agents. 23(3), 296-299 (2004).
51. Hansen GT, Blondeau JM. Comparison of the minimum inhibitory, mutant prevention and minimum bactericidal concentrations of ciprofloxacin, levofloxacin and garenoxacin against enteric Gram-negative urinary tract infection pathogens. J. Chemother. 17(5), 484-492 (2005).
52. Deshpande LM, Diekema DJ, Jones RN. Comparative activity of clinafloxacin and nine other compounds tested against 2000 contemporary clinical isolates from patients in United States hospitals. Diagn. Microbiol. Infect. Dis. 35(1), 81-88 (1999).
53. Rolston KV, Frisbee-Hume S, LeBlanc BM, Streeter H, Ho DH. Antimicrobial activity of a novel des-fluoro (6) quinolone, garenoxacin (BMS-284756), compared to other quinolones, against clinical isolates from cancer patients. Diagn. Microbiol. Infect. Dis. 44(2), 187-194 (2002).
54. Thornsberry C, Sahm DF, Kelly LJ et al.. Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999-2000. Clin. Infect. Dis. 34(Suppl. 1), S4-S16 (2002).
55. Karlowsky JA, Thornsberry C, Critchley IA et al.. Susceptibilities to levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis clinical isolates from children: results from 2000-2001 and 2001-2002 TRUST studies in the United States. Antimicrob. Agents Chemother. 47(6), 1790-1797 (2003).
56. Zhanel GG, Hisanaga TL, Laing NM et al.. Antibiotic resistance in Escherichia coli outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA). Int. J. Antimicrob. Agents. 27(6), 468-475 (2006).
57. Critchley IA, Jones ME, Heinze PD et al.. In vitro activity of levofloxacin against contemporary clinical isolates of Legionella pneumophila, Mycoplasma pneumoniae and Chlamydia pneumoniae from North America and Europe. Clin. Microbiol. Infect. 8(4), 214-221 (2002).
58. Roblin PM, Reznik T, Kutlin A, Hammerschlag MR. In vitro activities of rifamycin derivatives ABI-1648 (Rifalazil, KRM-1648), ABI-1657, and ABI-1131 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae. Antimicrob. Agents Chemother. 47(3), 1135-1136 (2003).
59. Kohlhoff SA, Roblin PM, Reznik T, Hawser S, Islam K, Hammerschlag MR. In vitro activity of a novel diaminopyrimidine compound, iclaprim, against Chlamydia trachomatis and C. pneumoniae. Antimicrob. Agents Chemother. 48(5), 1885-1886 (2004).
60. Hammerschlag MR, Roblin PM. The in vitro activity of a new fluoroquinolone, ABT-492, against recent clinical isolates of Chlamydia pneumoniae. J. Antimicrob. Chemother. 54(1), 281-282 (2004).
61. Dubois J, St-Pierre C. Comparative in vitro activity and post-antibiotic effect of gemifloxacin against Legionella spp. J. Antimicrob. Chemother. 45(Suppl. 1), 41-46 (2000).
62. Stout JE, Sens K, Mietzner S, Obman A, Yu VL. Comparative activity of quinolones, macrolides and ketolides against Legionella species using in vitro broth dilution and intracellular susceptibility testing. Int. J. Antimicrob. Agents. 25(4), 302-307 (2005).
63. Waites KB, Crabb DM, Bing X, Duffy LB. In vitro susceptibilities to and bactericidal activities of garenoxacin (BMS-284756) and other antimicrobial agents against human mycoplasmas and ureaplasmas. Antimicrob. Agents Chemother. 47(1), 161-165 (2003).
64. Waites KB, Crabb DM, Duffy LB. Comparative in vitro activities of the investigational fluoroquinolone DC-159a and other antimicrobial agents against human mycoplasmas and ureaplasmas. Antimicrob. Agents Chemother. 52(10), 3776-3778 (2008).
65. Duffy LB, Crabb DM, Bing X, Waites KB. Bactericidal activity of levofloxacin against Mycoplasma pneumoniae. J. Antimicrob. Chemother. 52(3), 527-528 (2003).
66. Dunbar LM, Wunderink RG, Habib MP et al.. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin. Infect. Dis. 37(6), 752-760 (2003).
67. Waites KB, Crabb DM, Duffy LB. Comparative in vitro susceptibilities and bactericidal activities of investigational fluoroquinolone ABT-492 and other antimicrobial agents against human mycoplasmas and ureaplasmas. Antimicrob. Agents Chemother. 47(12), 3973-3975 (2003).
68. Felmingham D, Feldman C, Hryniewicz W et al.. Surveillance of resistance in bacteria causing community-acquired respiratory tract infections. Clin. Microbiol. Infect. 8(Suppl. 2), 12-42 (2002).
69. Canton R, Morosini M, Enright MC, Morrissey I. Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programme. J. Antimicrob. Chemother. 52(6), 944-952 (2003).
70. Higgins PG, Fluit AC, Milatovic D, Verhoef J, Schmitz FJ. Mutations in GyrA, ParC, MexR and NfxB in clinical isolates of Pseudomonas aeruginosa. Int. J. Antimicrob. Agents. 21(5), 409-413 (2003).
71. Deryke CA, Du X, Nicolau DP. Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae. J. Antimicrob. Chemother. 58(3), 601-609 (2006).
72. LaPlante KL, Rybak MJ, Tsuji B, Lodise TP, Kaatz GW. Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin. Antimicrob. Agents Chemother. 51(4), 1315-1320 (2007).
73. Sahm DF, Benninger MS, Evangelista AT, Yee YC, Thornsberry C, Brown NP. Antimicrobial resistance trends among sinus isolates of Streptococcus pneumoniae in the United States (2001-2005). Otolaryngol. Head. Neck. Surg. 136(3), 385-389 (2007).
74. West M, Boulanger BR, Fogarty C et al.. Levofloxacin compared with imipenem/ cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: a multicenter, prospective, randomized, open-label study. Clin. Ther. 25(2), 485-506 (2003).
75. Chow AT, Fowler C, Williams RR, Morgan N, Kaminski S, Natarajan J. Safety and pharmacokinetics of multiple 750-milligram doses of intravenous levofloxacin in healthy volunteers. Antimicrob. Agents Chemother. 45(7), 2122-2125 (2001).
76. Chien SC, Wong FA, Fowler CL et al.. Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers. Antimicrob. Agents Chemother. 42(4), 885-888 (1998).
77. Stein GE, Schooley SL, Nicolau DP. Urinary bactericidal activity of single doses (250, 500, 750 and 1000 mg) of levofloxacin against fluoroquinolone-resistant strains of Escherichia coli. Int. J. Antimicrob. Agents. 32(4), 320-325 (2008).
78. Gotfried MH, Danziger LH, Rodvold KA. Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. Chest 119(4), 1114-1122 (2001).
79. Rodvold KA, Danziger LH, Gotfried MH. Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults. Antimicrob. Agents Chemother. 47(8), 2450-2457 (2003).
80. Capitano B, Mattoes HM, Shore E et al.. Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults. Chest 125(3), 965-973 (2004).
81. Conte JE Jr, Golden JA, McIver M, Little E, Zurlinden E. Intrapulmonary pharmacodynamics of high-dose levofloxacin in subjects with chronic bronchitis or chronic obstructive pulmonary disease. Int. J. Antimicrob. Agents. 30(5), 422-427 (2007).
82. Drusano GL, Preston SL, Gotfried MH, Danziger LH, Rodvold KA. Levofloxacin penetration into epithelial lining fluid as determined by population pharmacokinetic modeling and Monte Carlo simulation. Antimicrob. Agents Chemother. 46(2), 586-589 (2002).
83. Pea F, Marioni G, Pavan F et al.. Penetration of levofloxacin into paranasal sinuses mucosa of patients with chronic rhinosinusitis after a single 500 mg oral dose. Pharmacol. Res. 55(1), 38-41 (2007).
84. Garraffo R, Lavrut T, Durant J et al.. In vivo comparative pharmacokinetics and pharmacodynamics of moxifloxacin and levofloxacin in human neutrophils. Clin. Drug Investig. 25(10), 643-650 (2005).
85. Poole M, Anon J, Paglia M, Xiang J, Khashab M, Kahn J. A trial of high-dose, short-course levofloxacin for the treatment of acute bacterial sinusitis. Otolaryngol. Head. Neck. Surg. 134(1), 10-17 (2006).
86. Peterson J, Kaul S, Khashab M, Fisher AC, Kahn JB. A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis. Urology 71(1), 17-22 (2008).
87. Klausner HA, Brown P, Peterson J et al.. A trial of levofloxacin 750 mg once daily for 5 days versus ciprofloxacin 400 mg and/or 500 mg twice daily for 10 days in the treatment of acute pyelonephritis. Curr. Med. Res. Opin. 23(11), 2637-2645 (2007).
88. Dunbar LM, Khashab MM, Kahn JB, Zadeikis N, Xiang JX, Tennenberg AM. Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens. Curr. Med. Res. Opin. 20(4), 555-563 (2004).
89. Shorr AF, Zadeikis N, Xiang JX, Tennenberg AM, Wes Ely E. A multicenter, randomized, double-blind, retrospective comparison of 5- and 10-day regimens of levofloxacin in a subgroup of patients aged > or =65 years with community-acquired pneumonia. Clin. Ther. 27(8), 1251-1259 (2005).
90. File TM Jr, Milkovich G, Tennenberg AM, Xiang JX, Khashab MM, Zadeikis N. Clinical implications of 750 mg, 5-day levofloxacin for the treatment of community-acquired pneumonia. Curr. Med. Res. Opin. 20(9), 1473-1481 (2004). (Pubitemid 39361352)
91. Shorr AF, Khashab MM, Xiang JX, Tennenberg AM, Kahn JB. Levofloxacin 750-mg for 5 days for the treatment of hospitalized Fine Risk Class III/IV community-acquired pneumonia patients. Respir. Med. 100(12), 2129-2136 (2006).
92. Khashab MM, Xiang J, Kahn JB. Comparison of the adverse event profiles of levofloxacin 500 mg and 750 mg in clinical trials for the treatment of respiratory infections. Curr. Med. Res. Opin. 22(10), 1997-2006 (2006).
93. Yee YC, Evangelista AT, Obot-Tucker M et al.. Five-year surveillance (2003-2007) of anti-pneumococcal activity of oral agents recommended for the empirical treatment of community-acquired pneumonia (CAP) in adults. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 17-20 September (2007).